MetaVia (MTVA) Free Cash Flow (2015 - 2025)
MetaVia's (MTVA) quarterly Free Cash Flow came in at -$4.9 million in Q4 2025, up 11.14% YoY from -$4.4 million in Q4 2024, and down 64.47% on a QoQ basis from -$3.0 million in Q3 2025.
MetaVia (MTVA) Free Cash Flow (2015 - 2025) Analysis & Trends
MetaVia (MTVA) has 11 years of Free Cash Flow data on file, last reported at -$4.9 million in Q4 2025.
- Quarterly Free Cash Flow rose 11.14% year-over-year to -$4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.7 million (up 36.48% YoY) and the FY2025 annual result came in at -$15.7 million, up 36.47% from the prior year.
- Free Cash Flow declined to -$4.9 million in Q4 2025, from -$3.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.8 million in Q4 2022 to a low of -$7.3 million in Q2 2024.
- A 5-year average of -$3.9 million and a median of -$3.2 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 254.72% — and 2025, when it surged 57.46%.
- Tracing MTVA's Free Cash Flow over 5 years: stood at -$2.9 million in 2021, then surged by 37.67% to -$1.8 million in 2022, then plunged by 88.27% to -$3.4 million in 2023, then sank by 60.76% to -$5.5 million in 2024, then rose by 11.14% to -$4.9 million in 2025.
- The last three Free Cash Flow figures came in at -$4.9 million (Q4 2025), -$3.0 million (Q3 2025), and -$3.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.86 Mn |
| Dec 31, 2025 | -4.86 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Dec 31, 2024 | -5.47 Mn |
| Dec 31, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Jun 30, 2024 | -7.25 Mn |
| Jun 30, 2024 | -7.25 Mn |
| Mar 31, 2024 | -6.45 Mn |
| Mar 31, 2024 | -6.45 Mn |
| Dec 31, 2023 | -3.40 Mn |
| Dec 31, 2023 | -3.40 Mn |
| Sep 30, 2023 | -2.85 Mn |
| Sep 30, 2023 | -2.85 Mn |